Robert Shurtleff, DO
Family Medicine · Pikeville, KYNPI 1992182869
Payments from drug & device makers
Across 268 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$981
- GSK$581
- AstraZeneca$529
- Abbott$326
- Boehringer Ingelheim$308
- Grifols USA, LLC$271
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,862100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 57 | $981 |
| GSK | 49 | $581 |
| AstraZeneca | 15 | $529 |
| Abbott | 12 | $326 |
| Boehringer Ingelheim | 21 | $308 |
| Grifols USA, LLC | 13 | $271 |
| Lilly USA, LLC | 15 | $259 |
| Dexcom, Inc. | 11 | $235 |
| Novartis | 11 | $200 |
| Pfizer | 7 | $124 |
| Novo Nordisk | 5 | $104 |
| Otsuka America Pharmaceutical, Inc. | 4 | $97 |
| Bayer | 5 | $81 |
| Amgen | 5 | $78 |
| Corcept Therapeutics | 4 | $69 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $61 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $57 |
| Daiichi Sankyo Inc. | 3 | $56 |
| Sanofi-aventis U.S. LLC | 3 | $50 |
| Sumitomo Pharma America, Inc. | 2 | $42 |
| Travere Therapeutics, Inc. | 2 | $34 |
| Eisai Inc. | 1 | $28 |
| Merck | 2 | $27 |
| Tonix Medicines, Inc. | 1 | $26 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Atricure, Inc. | 1 | $22 |
| Exact Sciences | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Sobi, Inc | 1 | $19 |
| Tris Pharma Inc | 1 | $18 |
| Ardelyx, Inc. | 1 | $16 |
| Myovant Sciences Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Evoke Pharma, Inc. | 1 | $14 |
| Calliditas Therapeutics US Inc. | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Exeltis, USA Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$287
- AIRSUPRA$287
- FREESTYLE LIBRE 3$136
How this compares
$4,862 in reported general payments places this provider in the 85th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 206 | $240,534 |
| OzempicSemaglutide | 162 | $171,621 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 141 | $137,368 |
| EliquisApixaban | 136 | $135,675 |
| FarxigaDapagliflozin Propanediol | 131 | $113,297 |
| JardianceEmpagliflozin | 91 | $85,920 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 102 | $68,364 |
| TrulicityDulaglutide | 35 | $56,608 |
| EntrestoSacubitril/Valsartan | 48 | $40,763 |
| JanuviaSitagliptin Phosphate | 33 | $38,295 |
| JanumetSitagliptin Phos/Metformin Hcl | 23 | $24,960 |
| LinzessLinaclotide | 33 | $21,275 |
| XareltoRivaroxaban | 30 | $20,100 |
| MyrbetriqMirabegron | 35 | $20,081 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 84 | $14,552 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $259 | $297,142241 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort | $529 | $200,703270 claims |
| Novo NordiskOzempic, Rybelsus | $104 | $182,756174 claims |
| GSKTrelegy Ellipta | $581 | $137,368141 claims |
| PfizerEliquis | $124 | $135,675136 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $308 | $92,659105 claims |
| MerckJanuvia, Janumet | $27 | $63,25556 claims |
| NovartisEntresto | $200 | $40,76348 claims |
| AbbVieLinzess | $981 | $21,27533 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $42 | $7,77412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Pikeville
- Suzanne FordPikeville$19K
- Brian SmithVersailles$7.7M
- Barbara Fleming-PhillipsLexington$1.4M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- John RichardLexington$226K
- Diego MastronardiBowling Green$196K
- James TurnboPaducah$124K
- Eleida Tur OlivaLexington$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.